Company & Sponsor Intelligence
Xenon Pharmaceuticals Inc.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting2
Completed0
Countries1
Therapeutic footprint
epilepsy
Indexed studies
NCT05718817An Open-label Study of XEN1101 in Epilepsy
epilepsy · United StatesPHASE3
epilepsy · United StatesPHASE3
NCT03796962A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
epilepsy · United StatesPHASE2
epilepsy · United StatesPHASE2
NCT05667142A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
epilepsy · United StatesPHASE3
epilepsy · United StatesPHASE3
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →